Drug class
EpCAM/CD3 trifunctional bispecific monoclonal antibody; antineoplastic immunotherapy
Mechanism of action
Binds EpCAM on tumour cells and CD3 on T cells, bringing immune effector cells into proximity with EpCAM-positive malignant cells. Its Fc region also engages accessory immune cells, supporting antibody-dependent cellular cytotoxicity and phagocytosis.
General use cases
- Historical EU indication: intraperitoneal treatment of malignant ascites in patients with EpCAM-positive carcinomas when standard therapy is not available or no longer feasible; marketing status and availability are jurisdiction-specific
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
